Sitaxentan API Manufacturers & Suppliers
Find, compare & contact
Join our notification list by following this page.
Click the button below to find out more
Click the button below to switch over to the contract services area of Pharmaoffer.
Looking for Sitaxentan API 184036-34-8?
- Description:
- Here you will find a list of producers, manufacturers and distributors of Sitaxentan. You can filter on certificates such as GMP, FDA, CEP, Written Confirmation and more. Send inquiries for free and get in direct contact with the supplier of your choice.
- API | Excipient name:
- Sitaxentan
- Synonyms:
- Sitaxsentan
- Cas Number:
- 184036-34-8
- DrugBank number:
- DB06268
- Unique Ingredient Identifier:
- J9QH779MEM
About Sitaxentan
Here, you can find what Sitaxentan is used for, in short. Sitaxentan was marketed under the trade name Thelin for the treatment of pulmonary arterial hypertension (PAH) by Encysive Pharmaceuticals until Pfizer purchased Encysive in February 2008. In 2010, Pfizer voluntarily removed sitaxentan from the market over concerns of hepatotoxicity.
Do you want to buy this product? Send an inquiry to the listed suppliers that meets your quality requirements
Sitaxentan is a type of Other calcium Channel Blockers
Other calcium channel blockers are a category of pharmaceutical active pharmaceutical ingredients (APIs) that work by inhibiting the influx of calcium ions into cells through voltage-gated calcium channels. These medications are primarily used to treat various cardiovascular conditions, such as hypertension (high blood pressure) and angina (chest pain).
Unlike commonly known calcium channel blockers like dihydropyridines and non-dihydropyridines, other calcium channel blockers encompass a diverse group of drugs that possess calcium channel-blocking activity but may have different chemical structures and mechanisms of action.
These APIs exert their therapeutic effects by binding to specific calcium channels in cardiac and smooth muscle cells, reducing calcium entry and subsequent muscle contraction. By doing so, they relax blood vessels, improve blood flow, and reduce cardiac workload, resulting in lower blood pressure and alleviation of angina symptoms.
Some examples of other calcium channel blockers include bepridil, mibefradil, and verapamil. These drugs may have additional effects beyond calcium channel blockade, such as antiarrhythmic properties or interactions with other receptor systems.
As with any medication, other calcium channel blockers may have potential side effects, including dizziness, flushing, constipation, and peripheral edema. Therefore, it is important to use these drugs under the supervision of a healthcare professional and follow the prescribed dosage instructions.
In conclusion, other calcium channel blockers are a diverse class of pharmaceutical APIs that act by blocking calcium channels, leading to decreased blood pressure and relief from angina. These medications offer an alternative treatment option for cardiovascular conditions and should be used as directed by a healthcare provider to ensure safety and efficacy.
